Journal
/
Biologie du développement
/
Use of Hematopoietic Stem Cell Transplantation to Assess the Origin of Myelodysplastic Syndrome
Journal JoVE
Biologie du développement
Un abonnement à JoVE est nécessaire pour voir ce contenu.  Connectez-vous ou commencez votre essai gratuit.
Journal JoVE Biologie du développement
Use of Hematopoietic Stem Cell Transplantation to Assess the Origin of Myelodysplastic Syndrome

Use of Hematopoietic Stem Cell Transplantation to Assess the Origin of Myelodysplastic Syndrome

9,682 Views

•

06:39 min

•

October 03, 2018

DOI:

10.3791/58140-v

DOI:
10.3791/58140-v

•

06:39 min
October 03, 2018

•

7 Views
, , ,
1Genetics Branch,Center for Cancer Research, National Cancer Institute, National Institutes of Health, 2LGI Flow Cytometry Core Facility,Center for Cancer Research, National Cancer Institute, National Institutes of Health

Summary

Automatically generated

We describe the use of hematopoietic stem cell transplantation (HSCT) to assess the malignant potential of genetically engineered hematopoietic cells. HSCT is useful for evaluating various malignant hematopoietic cells in vivo as well as generating a large cohort of mice with myelodysplastic syndromes (MDS) or leukemia to evaluate novel therapies.

Explore More Videos

Hematopoietic Stem Cell TransplantationMyelodysplastic SyndromeCancer Stem CellsFunctional AnalysisDisease Initiating CellsAdoptive TransferTotal Body IrradiationBone Marrow Nucleated CellsFlow SortingBiotinylated Anti-lineage AntibodyAPC Conjugated Anti-Sca1 Antibody

Read Article

Cite this Article

Chung, Y. J., Khawaja, G., Wolcott, K. M., Aplan, P. D. Use of Hematopoietic Stem Cell Transplantation to Assess the Origin of Myelodysplastic Syndrome. J. Vis. Exp. (140), e58140, doi:10.3791/58140 (2018).

Download .ris file

Copy

Share Video

.

Copy